Department of Planning and Budget
2015 Fiscal Impact Statement

1. **Bill Number:** HB1458

House of Origin	⊠ Introduced	☐ Substitute	☐ Engrossed
Second House	☐ In Committee	☐ Substitute	☐ Enrolled

2. **Patron:** O'Bannon

3. **Committee:** Health, Welfare and Institutions.

4. **Title:** Naloxone; administration in cases of opiate overdose.

5. **Summary:** Naloxone; administration in cases of opiate overdose. Allows a prescriber to prescribe naloxone to a patient for administration to a person other than the patient when the patient believes the person is experiencing or is about to experience a life-threatening opiate overdose and allows a person to possess naloxone and administer naloxone to a person experiencing or about to experience a life-threatening opiate overdose. The bill provides that a person who administers naloxone to another person under such circumstances shall not be liable for civil damages and that a prescriber shall not be civilly or criminally liable for injuries resulting from the prescription of naloxone to a patient for administration to another person. The bill also allows emergency medical services personnel and other first responders to possess and administer naloxone pursuant to a standing order or oral or written protocol, and provides that first responders and members of emergency medical services personnel who administer naloxone pursuant to a standing order or oral or written protocol shall not be civilly or criminally liable for injuries resulting from the administration of naloxone.

6. **Budget Amendment Necessary**: No.

7. **Fiscal Impact Estimates:** Final.

8. **Fiscal Implications:** This legislation has no fiscal impact. The Department of Behavioral Health and Developmental Services currently operates a pilot program related to the administration of Naloxone. This legislation would not increase the responsibilities of the department.

9. **Specific Agency or Political Subdivisions Affected:** Local emergency medical services.

10. **Technical Amendment Necessary:** No.

11. **Other Comments:** None.